Blue Cross and Blue Shield of Florida
An Independent Licensee of the Blue Cross and Blue Shield Association.

Fact Sheet
Medicare Coverage Policies
Myth: Blue Cross and Blue Shield of Florida implemented this policy.
Fact: Blue Cross and Blue Shield of Florida performs its Medicare Part B business under
contract with the federal government. Medicare contracts are performed on a cost
reimbursement basis. Under contract, the Part B carrier is obligated to implement coverage
policies that will protect Medicare and its 3.2 million beneficiaries across the state.
Myth: Florida is the only state to have considered this type of skin lesion policy.
Fact: While Florida was the first state to implement this type of policy, two other states
(Mississippi and Rhode Island) have already implemented similar policies for the removal of
skin lesions; and more are close behind. Florida has consistently been a leader among
Medicare carriers in the country in many areas, including our claims payment system and our
efforts to fight fraud, waste and abuse.
Myth: Medicare doesn't pay for the removal of any skin lesions.
Fact: Medicare does pay for the removal of benign or pre-malignant skin lesions when it is
medically necessary for the patient to have them removed, based on medical research and
scientific data from leading experts in the field. Since the policy was implemented in November
1996, Medicare has paid more than go-percent of the claims submitted.
Myth: Medicare is telling my physician how to practice medicine.
Fact: Medicare reimburses physicians for services that are medically necessary and
reasonable for the beneficiary. The skin lesion policy outlines when physicians will be
reimbursed for the removal of skin lesions -- it does not outline how the physician should
practice medicine. All medical decisions should be made between the physician and patient.
We strongly encourage any patient who has a skin lesion to visit their physician right
away -- Medicare will pay for the physician visit.
Myth: Medicare doesn't care about the health of seniors.
Fact: Medicare is very concerned about the quality of health care that Medicare beneficiaries
receive in Florida. It is our duty to safeguard the Medicare system, and the federal government
has entrusted us to do so. It is also our responsibility to make sure that we cover only services
for beneficiaries that are medically necessary and reasonable. Medicare works across the
state to educate beneficiaries on what Medicare covers and explain their Medicare benefits.
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CLINICAL LABORATORY SERVICES
Blood tests, urinalysis, and more.
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Unlimited if medically
necessary.

Nothing for services.
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OUTPATIENT HOSPITAL TREATMENT

Unlimited if medically
Services for the diagnosis or treatment of an illness I necessary.
or injury.
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approved amount.
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Medicare payment to
hospital based on hospital
costs.

20% of billed amount
(after $100 deductible).*
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·starting with 4th pint).

· additional pints (after
$100 deductible). ***

* Once you have had $100 of expense for covered services, the Part B deductible does not apply to any other covered services
you receive for the rest of the year.
** Federal law limits charges for physician services (see page 7).
*** To the extent any of the three pints of blood are paid for or replaced under one part of Medicare during the calendar year they
do not have to be paid for or replaced under the other part.
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DEFINITIONS OF SOME MEDICARE TERMS
Excess Charge: The difference between the
Medicare-approved amount for a service or
supply and the actual charge, if the actual
charge is more than the approved amount.

Actual Charge: The amount a physician or
supplier actually bills for a particular medical
service or supply.
Approved Amount: The amount Medicare
determines to be reasonable for a service that
is covered under Part B of Medicare. It may be
less than the actual charge. For many services,
including physician services, the approved
amount is taken from a fee schedule that assigns a dollar value to all Medicare-covered
services that are paid under that fee schedule.

Limiting Charge: The maximum amount a
physician may charge a Medicare beneficiary
for a covered physician service if the
physician does not accept assignment of the
Medicare claim. The limit is 15% above the
fee schedule amount for non-participating physicians. Limiting charge information appears on Medicare's Explanation of
Medicare Benefits (EOMB) form.

Assignment: An arrangement whereby a physidan or medical supplier agrees to accept the
Medicare-approved amount as full payment
for services and supplies covered under Part B.
Medicare usually pays 80% of the approved
amount directly to the physician or supplier
after the beneficiary meets the annual Part B
deductible of $100. The beneficiary pays the
other 20%.

Medicare Carrier: An insurance organization under contract to the federal government
to process Medicare Part B claims from
physicians and other suppliers. The names and
addresses of the carriers and areas they serve
are listed in the back of The Medicare Handbook, available from any Social Security Administration office.

Benefit Period: A benefit periQd is a way of
measuring a beneficiary's use of hospital and
skilled nursing facility services covered by
Medicare. A benefit period begins the day the
beneficiary is hospitalized. It ends after the
beneficiary has been out of the hospital or
other facility that primarily provides skilled
nursing or rehabilitation services for 60 days
in a row. If the beneficiary is hospitalized after
60 days, a new benefit period begins, most
Medicare Part A benefits are renewed, and the
beneficiary must pay a new inpatient hospital
deductible. There is no limit as to the number
of benefit periods a beneficiary can have.

Medicare Hospital Insurance: This is Part A
of Medicare. It helps pay for medically neces-.
sary inpatient care in a hospital, skilled nursing facility or psychiatric hospital, and for
hospice and home health care.
Medicare Medical Insurance: This is Part B
of Medicare. This part helps pay for medically
necessary physician services and many other
medical services and supplies not covered
by Part A.

Coinsurance: The portion or percentage of
the Medicar~approved amount that a beneficiary is responsible for paying.

Participating Physician and Supplier: A
physician or supplier who agrees to accept
assignment on all Medicare claims.

Deductible: The amount of expense a beneficiary must first incur before Medicare begins
payment for covered services.
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Coverage for Benign or Premalignant Skin Lesion Removal
i Background
I

Medicare B ofFlorida has developed a medical policy for these services as well as services for the removal of benign, either by shaving or excision (procedure codes 113 00
through 11446); the destruction of benign facial or premalignant skin lesions in any location (p(ocedure codes 17000 through 17002) destruction by any method of
complicated benign or premalignant lesions (procedure code 1701 0); destruction by any method benign or premalignant lesion on any area other than face ( 1710 l through
17105); and the destruction by any method of flat warts or molluscum contagiosum and milia ( 17110).

Covered Conditions and/or Diagnoses

M-~dicare B will consider the destruction of a benign or premalignant skin
• lesion medically necessary under the following circumstances:
• • When the patient has multiple actinic keratoses and has self-administered 2%
to 5% Fluorouracil topical cream for two to four weeks and the actinic
keratoses have not responded to this treatment one to two months following
treatment•, m:
*

NonCovered
Condition
and/or
Diagnoses

All other indications
l

It should be noted that the natural response to fluorouracil (Efudex) is
erythema, usually followed by vesiculation, desquamation, erosion and
reepithelialization. Therefore, during ~d immedicately following
fluorouracil treatment these signs and symptoms would be considered
part of the healing process and would not be considered as meeting the
criteria for removal. There are contraindications for topical
fluorouracil which include pregnancy, use on mucous membranes, use
on mouth, and use around eyes or on nose. If after two months
following treatment with fluorouracil, the actinic keratoses have not
responded, they may be removed or destroyed.

• When a patient presents with an actinic keratosis that has changed in size, has
developed erythema, has thickened, has ulcerated, has eroded, has developed
changes at the tumor margins, has become markedly hyperkeratotic, in which
pain has developed and/or a cutaneous horn has developed;
• When the patient presents with an actinic cheilitis (actinic keratosis of the
lower lip) or an actinic keratosis on the upper lip;
• When the patient presents with an actinic conjunctivae (actinic keratosis of the
conjunctiva);
• When the patient presents with an actinic keratosis on the nose, ear or eyelid;
• When the patient presents with a actinic keratosis and has a history of one of
the following:
chronic immunosuppression such as that associated with organ transplantation, particularly renal transplantation, and other disease processes such
as Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome {AIDS) and/or chronic lymphocytic leukemia or
lymphoma;
- treatment of psoriasis with psolaren-ultraviolet A (PUVA) therapy;
xerodenna pigmentosum, albinism, or discoid lupus erythematosus;
and/or,

.

•--

•

Subject
to
Waiver

Comments

Coding Guidelines
CPT coding is based on the type of lesion (benign or premalignant),
method of destruction or removal, and the number of lesions removed
for any of the procedure codes within the following ranges: 113 0011313; 11400-11446; 17000-17002; or 17100-17110.
If a lesion is destroyed or removed for any reason or for any circumstance other than ones listed in this article, the procedure is
considered medically unnecessary and is, therefore, not reimbursurable by Medicare.

Medical
Necessity
Yes
(Refer
to
guidelines
outlined in
the Column
titled "Cov- ·
When the patient is seen in the office for purposes of prescribing
ered Conditions and/or fluorouracil and providing instruc\.ion on how to use this medication, the appropriate level of Evaluation and Management service
Diagnoses")
may be billed •
Procedure code 17000 may only be billed once per day. Procedure
Utilization
code 17001 may be billed no more than two times in one day because
Yes
the descriptor reads "2nd and 3rd lesion, each lesion". It is not appropriate to use the modifier-76 (repeat procedure) with these codes.
Procedure codes 17100 through 17104 are to be billed in a similar
manner. The first lesion should be billed utilizing procedure code
17100. If a second lesion is removed, it should be billed utilizing procedure code 17101. If three to fifteen lesions are removed on the same
day as the first and second, procedure code 17102 may also be billed.
Procedure code 17104 is used when fifteen or ~ore lesions are removed. It is not appropriate to bill this code with 17100, 17101, or
17102 m: to bill with the modifier -76.

•

Coverage for Benign or Premalignant Skin Lesion Removal (con't)
Covered Conditions and/or Diagnoses (con't)

- previous treatment of a biopsy-proven Squamous Cell Carcinoma (SCC).
• When a patient presents with an arsenical keratosis (due to arsenic exposure);
• When a patient presents with a keratosis and has a history of significant exposure to therapeutic
or occupational radiation therapy (chronic radiation kertosis).
• When a patient presents with a keratosis which arises from an old scar (chronic cicatrix
keratosis).
If none of the aforementioned conditions exist, Medicare B of Florida would consider
the removal of an actinic keratosis as medically unnecessary and, therefore, not reimbursable by Medicare.
In addition, chemical peels of the face, even in the presence of actinic keratoses, are
considered medically unnecessary in nature because the technique is used to improve the
appearance of photodamaged skin~ and is, therefore, not reimbursable by Medicare.
The total number ofservices billed utilizing procedure codes 17000, 17001, .and.17002
which exceed the number that woul~ be considered medically necessary and rea~onable
according to established parameters will be reviewed on a prepayment basis using the criteria above and may be denied as not medically necessary or reasonable.
Generally, the removal of benign lesions such as seborrheic keratoses, sebaceous cysts, and
warts are done for cosmetic reasons, however, in mt instances it may be necessary to remove
these types of lesions. Medicare B of Florida will consider the removal of these lesioris as
medically necessary for any of the following reasons:

: • the lesion is in an area such as the neck or waist and is constantly irritated and/or is located in
an anatomical location of recurrent trauma and that such trauma has in fact occurred;
• the lesion obstructs an orifice or clinically obstructs vision (this would include any lesion);
· • the patient presents with condylomata acuminta (venereal warts) and/or is immunosuppressed;
and/or,
I • plantar warts or other lesions on the sole of the foot which impede the patient's ability to
ambulate or which meet any of the aforementioned criteria.
If the aforementioned signs and symptoms are not present, further treatment would
! be considered medically unnecessary in nature and, therefore, not reimbursable by Medi1

care.
Destruction of benign or premalignant lesions that exceed utilization parameters as
determined by our analysis of frequency data for beneficiaries may be reviewed for medical necessity on a prepayment basis.

Comments (con't)

Documentation Requirements:
If the patient presents with multiple actinic keratoses, the self-administration of topical
2% to 5% fluorouracil cream or solution for a period of no less than two weeks and unresponsiveness to the medication after two months should be documented. If the patient has
a condition in which fluorouracil is contraindicated such as pregnancy or actinic keratosis
(es) around the eyes on the nose, on the mouth, or on mucous membranes, the physician's
office/progress note should reflect this. The location of the lesion(s) should be documented as well.
If the patient presents with an actinic keratosis(es) and its appearance has changed, i.e.
size, erythema, thickening, ulceration, and/or erosion in the tumor or tumor margins m if
the patient has developed pain within the lesion, this should be clearly documented in the
physician's progress/office note to substantiate removal of the lesion.
If the patient presents with an actinic cheilitis (actinic keratosis of the lower lip) or an
actinic keratosis on the car or conjunctiva, the exact location and a description of the lesion's appearance should be documented in the physician's progress/office note.
If the patient presents with an actinic keratosis and has a history of chronic irnrnunosuppression; treatment of psoriasis with PUVA therapy; xcrodcrma pigmentosum, disco id
lupus erythematosus or albinism; and/or a previous treatment of a biopsy-proven SCC, this
should clearly be documented in the physician's progress/office note. The approximate
starting date and duration of radiation therapy or PUVA therapy should be documented, if
applicable. In addition, the date of organ transplantation should be documented, if applicable. Any other immunosuppressive disorder should be documented with the date or approximate date of diagnosis.
Also, if the patient has had a previous biopsy-proven SCC or other skin malignancy,
the location of that lesion, the date of removal, and a pathology report for the previous lesion, if available, should be documented. In addition, for the aforementioned conditions/treatments, the exact location and a description of the lesion should be documented.
For cicatrix keratoses, the location of the scar, the type of the scar, the approximate
date the scar developed, and a description of the size, location and appearance of the lesion
should be documented in the physicians' progress/office note.
Although not required at this time, a photograph of the lesion with an indication of the
size and location would be an excellent documentation 'tool for the size, location, and appearance of the lesion. If the physician is not able to take a photograph or make a sketch
in his/her notes regarding size, location, and appearance of the lesion, a very clear description of the lesion must be included in the progress/office note.
For those benign lesions that are located in areas which subject the lesion to constant irritation and/or trauma and need to be removed because of constant or frequent
traumatization, the exact location and size of the lesion and type of irritation and/or trauma
should be documented in the physician's progress note/office note.
In addition, to the above, the method of destruction or removal should be described in the physician's progress/office note for any type oflesion destroyed or removed.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __J .____ _ _ _ _ _ _ _ _ _ _ _ _ __ ,

October 1996
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CLARIFICATION OF MEDICAL POLICY
FOR SKIN LESION REMOVAL

The purpose of this communication is to clarify the reference to
Efudex topical cream contained in our local medical review policy
(LMRP) for skin lesion removal.
This policy was published in the
October, 1996 special edition of the "Medicare B Update!"
The above referenced policy in no way circumvents physician
judgment. The skin lesion LMRP simply seeks to articulate when
excision or destruction (e.g., laser treatment, chemical treatments} is
considered medically necessary. There are clinical criteria cited in the
skin lesion LMRP that constitute appropriateness.
Several of the
criteria are:
•

When the patient presents with an actinic keratosis that has
changed in size, has developed erythema, has thickened, has
ulcerated, has ernded, has developed changes at the tumor
margins, has become markedly hyperkeratotic, in which pain has
developed and/or a cutaneous horn has developed;

•

When the patient presents with an actinic keratosis
lower-lip, upper-lip, conjunctivae, nose, ear, or eyelid;

•

When the patient presents with actinic keratosis and has a
history of one of the following: chronic immunosuppression,
treatment of psoriasis with psoralen-ultrayiolet A (PUVA)"
therapy, xeroderma pigmentosum, albinism, or· discoid lupus
erythematosus, and/or previous treatment of a biopsy-proven
Squamous Cell Carcinoma or other skin malignancy;

•

When a patient presents with a keratosis and has a history of
significant exposure to therapeutic or occupational radiation
therapy;

•

When the patient has multiple actinic keratoses and has selfadministered 2% to 5% Efudex topical cream for two to four
weeks and the actinic keratoses have not responded to this
treatment one to two months following treatment.

(
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There has been considerable misunderstanding of the reference to
Efudex. A fundamental principal in the policy is that treatment of
asymptomatic actinic keratosis is medically unnecessary. This would
be true for any method of treatment, e.g., surgical, laser or cryogenic
destruction, or use of topical creams. (chemical destruction). Because
literature indicates that lesions failing topical treatment with Efudex
suggests a higher likelihood of malignancy, we have allcwed · for
coverage in these cases.
In other words, a failure of Efudex
establishes a clinical criterion for a lesion being suspicious versus
asymptomatic.
In short, our skin lesion LMRP lays out the criteria for when the
removal of skin lesions is appropriate.
The policy both reduces
inappropriate billing and protects beneficiaries from unnecessary
procedures. Should additional medical literature or other information
relevant to this matter become available, providers are always free to
contact us and request policy changes. In addition, we continue to
offer formal appeal rights to providers who believe their claims were
improperly denied.
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